Revenue Up 36% to 47.2 Billion Won, Profit Structure Improved

Bone Substitute Sales Triple, Driving Performance Rebound

Cigemedtec has achieved a turnaround to operating profit, driven by the growth of its bone substitute and dental businesses.

Cizimedtec company logo image. Cizimedtec

Cizimedtec company logo image. Cizimedtec

View original image

On March 26, Cigemedtec announced that its consolidated operating profit for 2025 reached 3.8 billion won, marking a turnaround from an operating loss of 1.1 billion won in the previous year.


During the same period, revenue amounted to 47.2 billion won, a 36% increase compared to the previous year. Net income also turned positive, reaching 6.5 billion won after recovering from a net loss the prior year.


Results on a separate basis also improved. Revenue rose by 33% to 30.1 billion won, and operating profit increased by 74% to 4 billion won. Net income turned positive at 8.5 billion won.


The growth was primarily led by the bone substitute business, with related revenue increasing approximately threefold from 2.6 billion won to 7.6 billion won. Sales of spinal products also expanded from 1.4 billion won to 2.4 billion won.



The dental and overseas businesses also contributed to improved performance. Revenue from the dental business, newly incorporated through mergers and acquisitions, was included, and the U.S. subsidiary saw revenue growth coupled with a reduction in operating losses.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing